HeartSciences Inc. Common Stock (HSCS) is a publicly traded Healthcare sector company. As of May 21, 2026, HSCS trades at $1.99 with a market cap of $5.92M and a P/E ratio of -0.40. HSCS moved +0.00% today. Year to date, HSCS is -37.34%; over the trailing twelve months it is -57.02%. Its 52-week range spans $1.77 to $6.47. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces HSCS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HeartSciences Secures First SaaS Revenue Deal for MyoVista Insights with St. Vincent Health: HeartSciences signed a commercial agreement with St. Vincent Health to deploy its MyoVista Insights ECG management platform under a SaaS recurring revenue model. This first mainstream revenue-generating deployment follows the full launch at the American College of Cardiology session and paves way for further hospital agreements.
| Metric | Value |
|---|---|
| Price | $1.99 |
| Market Cap | $5.92M |
| P/E Ratio | -0.40 |
| EPS | $-4.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.47 |
| 52-Week Low | $1.77 |
| Volume | 145 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.67K |
| Net Income | $-8.49M |
| Gross Margin | 57.92% |
2 analysts cover HSCS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.